“GlaxoSmithKline has been trialling a new, long lasting injectable HIV drug against the currently available daily pill to prevent HIV infection in men.
However, the tests have been so positive that the trial has been stopped early by independent scrutineers.
The new treatment, Cabotegravir, is 69% more effective than the daily pill, Truvada, currently available from US drug giant Gilead.
The results of the trial have come as something of a shock to the scientific community. Phase III trials are rarely stopped midway because they are so effective.” Read more…